,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'breast', 'destiny-breast04']
 asco expert shares how the destiny-breast04 trial will redefine how #breastcancer is classified and expand the population of pts who can benefit from her2-targeted therapy #asco22 #bcsm 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.